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The Anisotropic Analytical Algorithm has been 
broadly utilized for dose calculation in the Eclipse 
treatment planning system. Van Esch et al. [1] re-
ported that AAA improves the accuracy of dose 
calculations, compared to the single pencil beam 
(SPB) algorithm, and can achieve 5% agreement 
with measurements in thoracic phantom. In spite of 
this, AAA has been noticed to significantly overesti-
AbstrAct
background: this study aimed to verify the dosimetric impact of acuros XB (aXB) (aXB, Varian Medical Systems Palo alto ca, 
USa), a two model-based algorithm, in comparison with anisotropic analytical algorithm (aaa) calculations for prostate, head 
and neck and lung cancer treatment by volumetric modulated arc therapy (VMat), without primary modification to aaa. at 
present, the well-known and validated aaa algorithm is clinically used in our department for VMat treatments of different 
pathologies. aXB could replace it without extra measurements. the treatment result and accuracy of the dose delivered de-
pend on the dose calculation algorithm.
Materials and method: ninety-five complex VMat plans for different pathologies were generated using the eclipse version 
15.0.4 treatment planning system (tPS). the dose distributions were calculated using aaa and aXB (dose-to-water, aXBw and 
dose-to-medium, aXBm), with the same plan parameters for all VMat plans. the dosimetric parameters were calculated for 
each planning target volume (PtV) and involved organs at risk (oaR). the patient specific quality assurance of all VMat plans 
has been verified by octavius®-4D phantom for different algorithms. 
results: the relative differences among aaa, aXBw and aXBm, with respect to prostate, head and neck were less than 1% for 
PtV D95%. however, PtV D95% calculated by aaa tended to be overestimated, with a relative dose difference of 3.23% in the 
case of lung treatment. the absolute mean values of the relative differences were 1.1 ± 1.2% and 2.0 ± 1.2%, when comparing 
between aXBw and aaa, aXBm and aaa, respectively. the gamma pass rate was observed to exceed 97.4% and 99.4% for the 
measured and calculated doses in most cases of the volumetric 3D analysis for aaa and aXBm, respectively.  
conclusion: this study suggests that the dose calculated to medium using aXBm algorithm  is better than aaa and it could be 
used clinically. Switching the dose calculation algorithm from aaa to aXB does not require extra measurements.
Key words: anisotropic analytical algorithm; planning target volume; volumetric modulated arc therapy; multi-leaf collimator; 
gamma index
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mate the dose near air-tissue interfaces [2]. A novel 
dose calculation algorithm called Acuros XB, which 
explicitly solves the Linear Boltzmann Transport 
Equation (LBTE), has been applied for clinical prac-
tice [3]. LBTE is the leading equation that describes 
the distribution of radiation particles resulting from 
their interactions with matter. AXB discretizes the 
space, angle, and energy variables of the LBTE into 
grids and computes the energy fluence variation of 
electrons and scattered photons in a substance. 
Han et al. [4] and Bush et al. [5] have shown that 
AXB could reach accuracy comparable to that of 
Monte Carlo methods, which are broadly consid-
ered the gold standard for precise dose calculation 
used in radiation therapy in phantom experiments, 
assuming the existence of homogeneous water 
and heterogeneous media. Several clinical studies 
have been performed for dosimetric comparison of 
VMAT and intensity modulated radiation therapy 
(IMRT) plans between AXB and AAA, indicating 
that AXB underestimated the doses to PTV or nor-
mal tissues in the cases of prostate, lung, head and 
neck and pelvis treatment, compared to AAA [6–9]. 
Compared to these results, another study has re-
vealed that AAA underestimated the dose to the 
spine [7]. The AXB and AAA difference depends on 
the treatment site and beam energy. AXB provides 
two dose reporting methods: dose-to-water (AXBw) 
and dose-to-medium (AXBm). For the AXBw, en-
ergy dependent fluence-to-dose response functions 
are based on water, whereas for the AXBm they are 
based on each material. It was a subject of debate 
whether to select AXBw or AXBm for clinical prac-
tice [8]. Walters et al. [8] have determined that the 
dose-to-water method offers a better evaluation of 
the dose to sensitive tissue in the bone, compared 
to the dose-to-medium one. 
The purpose of this study is to ascertain that 
implementing the new dose computation algorithm 
will not majorly change the clinical treatment plans 
in our department. The study clearly helps new cen-
ters that are willing to switch the TPS from AAA to 
AXB. The pre-treatment patient-specific quality as-
surance with the Octavius system will additionally 
boost up the clinical results.
Materials and methods
Ninety-five patients, who had undergone treat-
ment in our institute during April–December 2019, 
were included into this study as shown in Table 1.
Dose calculation and planning
For all the three types of pathologies, VMAT 
plans were generated by the Eclipse TPS for a Clin-
ac iX accelerator, equipped with a Millennium 120 
multileaf collimator (MLC) (Varian Medical Sys-
tems. Palo Alto. CA. USA), using 6 and 18 MV pho-
ton beams. The VMAT plan was created in AXBm. 
For the prostate cases, the total dose prescribed to 
the PTV was 76 Gy, with a daily dose of 2.0 Gy in 38 
fractions. The prostate VMAT plans were generated 
using two full arcs with 6 & 18 MV photon beams, 
as needed. The head and neck VMAT plans were 
generated by using two or three full arcs with a 6 
MV photon beam and the total prescription dose to 
PTV was 70 Gy (2.0 Gy/fraction). The prostate and 
head and neck cases were treated in simultaneous 
integrated boost (SIB) fractionation schemes. The 
greatest dose was mentioned for the study. For lung 
SBRT cases, the prescription dose to PTV was 48 Gy 
in 4 fractions of 80% of isodose. The VMAT plans 
for lung SBRT were made using two or three partial 
arcs with 6 MV photon beam. The dose calculation 
grid used in this study was 2.5 mm, except for 1.0 
mm for lung SBRT cases. Then, each plan was recal-
culated for AAA and AXBw, while maintaining the 
AXBm calculated monitor units, leaf motion, and 
beam arrangement. The beam models in AAA and 
AXB were based on the same physical data.
evaluation of dosimetric parameters
For the sake of comparison, the relative dose and 
volume differences in the corresponding dose-vol-
table 1. number of patients and applied treatment techniques
Pathologies Number of patients Treatment techniques
Prostate 35 VMat
head and neck 35 VMat
lung 25 SBRt
VMat — volumetric modulated arc therapy; SBRt — stereotactic body radiation therapy
Raju P. Srivastava et al. acuros XB — analytical anisotropic algorithm for volumetric modulation arc therapy
483https://journals.viamedica.pl/rpor
umetric parameters, obtained by AAA and AXB for 
the same case, were calculated as follows [10]:
Relative difference (%) = 𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉 𝑉 𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉 𝑉× 𝑉100 
where: AXBx is selected between AXBw and 
AXBm depending on what dose reporting mode 
should be compared. 
evaluation of the plans and statistical 
analysis 
For the PTV, the evaluation parameters included 
D95%, D98%, minimum dose and the mean dose. For 
the OARs, the analysis included the mean dose and 
a set of appropriate Vx values, Vx being the volume 
of the organ getting a dose of x or more. In the case 
of OARs, the analysis included an appropriately 
selected dose or volume parameter. For the rectum 
and bladder, V30, defined as the volume that re-
ceives more than 30 Gy, was analyzed. The absolute 
doses in this study were presented in Gy and all the 
numerical data were rounded to the nearest tenth.
octavius phantom 
The 2D-Array, together with Octavius®‐4D 
(PTW-Freiburg, Germany), have been widely de-
scribed in the literature [11–13]. Figure 1 shows 
the normal setup of Octavius®‐4D with the 2D array 
detector. An inclinometer mounted on the gantry 
ensures that the rotation unit always rotates along 
with the gantry, always keeping the 2D array per-
pendicular to the beam axis. The beam always hits 
the detector array in a perpendicular way, because 
the same face of the detector follows the gantry, so 
no correction factors are required.
To evaluate the dosimetric agreement between the 
measured and the calculated dose, the gamma evalu-
ation method, implemented in the Verisoft 7.2.0 ver-
sion, was used, where the measured dose matrix was 
used as reference. This calculation of the gamma in-
dex is based on the concept Low [14]. A two-sample 
paired t-test was used to compare the results for the 
average dose D95%, D98% and Dmax of PTV prostate, 
head and neck and lung pathologies. A p-value < 0.05 
was considered statistically significant. 
Results
The relative differences among AAA, AXBw and 
AXBm, with respect to prostate, head and neck and 
lung cases, are shown in Figure 2. The PTV D95% 
and D98% were within 1.0 ± 0.23% difference be-
tween AXBw and AXBm to the AAA algorithm, for 
the prostate and head and neck cases, however, the 
value increases up to 3.23 ± 0.26% for the lung cases 
treatment by SBRT. Bladder V30 shows 1.3 ± 0.31% 
and 2.6 ± 0.29% difference between AAA and 
AXBw, AXBm, respectively. The maximum difference 
was found to be 4% for esophagus mean dose and 
2.12% in Dmax spinal cord in the treatment of head 
and neck pathologies. The maximum dose to the 
thoracic wall was underestimated with maximum 
value of the relative dose difference of 3.95% from 
AAA during the treatment of SBRT.
Several factors may explain the fact that no sig-
nificant dose differences were found at the level of 
the spinal cord. Unlike the lungs, the spinal cord 
receives most of its dose by scatter. Additionally, the 
much lower density of the lungs, compared to wa-
ter, can easily result in higher difference in different 
dose calculation algorithms because of increased 
electron interaction paths. Whether dose compu-
tation algorithms compute significantly different 
Figure 1. Standard setup of octavius®‐4D system in 
measurement position with Detector 1500 inserted in a 
cylindrical phantom that rotates synchronously with the 
gantry and the inclinometer attached to the gantry
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doses in lower or higher density regions depends on 
the fine details of the dose computation methods, 
such as scaling of the pre-computed Monte Carlo 
kernels with respect to density. 
The average dose D95%, D98% and Dmax of PTV with 
respect to prostate, head and neck and lung cases 
for AAA, AXBw, and AXBm are shown in Table 2. 
The p-value has been calculated for the average 
dose D95%, D98% and Dmax of PTV between AAA, 
AXBw, and AXBm. These results were found signifi-
cant (p < 0.05) for AAA and AXB to all pathologies.
All the plans were analyzed [14] and the γ-pass 
rate with the 3% dose tolerance and 3 mm dis-
tance was calculated to harmonize the relation to 
the treatment planning system. Table 3 summa-
rizes the results of the average g-passing rate for 
the different pathologies examined in the pres-
ent study, by 2D and 3D analysis for AAA, AXBw 
and AXBm. The results demonstrated that the 
gamma pass rates for all the plans were higher 
than ≤ 97.0 % by volumetric 3D analysis, where 
a 10% low-dose threshold was fixed [15]. Our clini-
Figure 2. the relative difference for planning target volume (PtV) and organ at risk for (A) prostate; (b) head and neck; 
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cal standard of 95% or greater for the gamma index 
percentage was standardized and was achieved for 
all the plans. 
Discussion
For many years, the methods used to inter-com-
pare the calculated doses to be delivered to different 
media have been subject to scientific debate [8]. 
This debate has generally addressed what is the best 
quantity to score (dose to medium or dose to water) 
with respect to the biological effect of radiation. 
Table 4 shows an overview of literature compari-
sons to the study.
Rana et al. [6] used Rapid Arc plans to perform 
a planning study of prostate cancer patients in 
which the clinical dosimetric effects of AAA and 
AXB were compared. Our results confirm their 
findings (range –0.21–0.67%) concerning the PTV 
D95%.
Kan et al. [16] reported that the mean and mini-
mum doses to the PTV70 calculated by AXB were 
reduced by AAA for nasopharyngeal carcinoma. 
They found –2.0% and 4.0% discrepancies for 
table 3. average γ-passing rates for aaa, aXBw and aXBm for different pathologies in planar 2D and volumetric 3D analysis. 





Gamma passing rates (%) for AAA
Prostate 95.8 ± 1.7 96.5 ± 0.2 96.2 ± 0.4 97.9 ± 1.2 
head and neck 97.2 ± 0.3 97.3 ± 1.1 98.1 ± 0.8 98.1 ± 1.1 
lung 91.8 ± 1.9 91.2 ± 0.5 94.7 ± 1.1 97.4 ± 1.4 
Gamma passing rates (%) for AXbw
Prostate 96.6 ± 0.3 95.8 ± 1.1 96.2 ± 0.6 97.5 ± 0.4 
head and neck 96.2 ± 0.3 96.9 ± 0.5 98.2 ± 0.5 98.7 ± 0.5 
lung 99.1 ± 0.1 99.2 ± 0.3 99.6 ± 0.1 99.7 ± 0.3 
Gamma passing rates (%) for AXbm
Prostate 96.8 ± 1.5 96.5 ± 1.3 97.4 ± 0.8 99.4 ± 0.6 
head and neck 97.4 ± 1.4 97.8 ± 1.5 97.6 ± 1.0 99.6 ± 0.3 
lung 95.8 ± 1.1 95.1 ± 1.1 99.6 ± 0.3 99.7 ± 0.1 
table 2. the planning target volume (PtV) dose (D95%, D98% and Dmax) for prostate, head and neck and lung cases. Statistical 
error indicates standard deviation. pa-m: p-value between aaa and aXBm. pa-w : p-value between aaa and aXBw
PTV AAA AXBm AXBw pA-m pA-w
Prostate
D95% 75 .53 ± 0 .6 74 .69 ± 0 .4 74 .96 ± 0 .3 0.01 0.006
D98% 74 .28 ± 0 .5 73 .89 ± 0 .3 74 .68 ± 0 .3 0.02 0.004
Dmax 79.43 ± 0.4 78.25 ± 0.4 80.59 ± 0.6 0.01 0.001
Head and neck
D95% 68 .97 ± 0 .8 68 .58 ± 0 .6 68 .88 ± 0 .6 0 .037 0 .026
D98% 68 .52 ± 0 .6 68 .59 ± 0 .3 68 .64 ± 0 .8 0 .022 0 .005
Dmax 74 .84 ± 1 .2 73 .86 ± 0 .9 74 .59 ± 1 .0 0 .031 0 .007
Lung
D95% 50 .01 ± 0 .9 48 .68 ± 0 .5 48 .51 ± 0 .4 0 .04 0 .06
D98% 48 .37 ± 1 .1 46 .93 ± 0 .8 46 .81 ± 0 .6 0 .02 0 .05
Dmax 60 .21 ± 0 .4 60 .12 ± 0 .5 60 .06 ± 0 .5 0 .01 0 .02
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AXBm and AXBw in bone content. The results of 
the current study showed that AAA computed, on 
average, an up to 1.01% higher maximum PTV 
dose than AXBm, which was used for generating the 
treatment plans. Hirata et al. [17] determined that 
AXB showed agreement with the measurements 
within 2.6% at the high-density area, while AAA 
and PBC calculations overestimated the dose by 
more than 4.5% and 4.0%, respectively. These find-
ings are in agreement to those of Fogliata et al. [18]. 
They showed the difference in the doses calculated 
using AXB and AAA was within 3% in lung plan-
ning target volumes. Bassi et al. [19] validated AXB 
in the presence of inhomogeneities for VMAT. They 
reported up to 1.8% dose calculated uncertainties 
with AXB. The absolute dose measured with Gaf-
Chromic EBT in the heterogeneous phantom in 
the abdominal region proved that the dose differ-
ences after the air calculated by AXB are less than 
3% while with AAA differences up to 11% can be 
obtained. Soh et al. [20] displayed ± 1.5% difference 
between AAA and AXB algorithm predicted depth 
dose, excluding the surface and buildup doses.
Han et al. [4] reported that AAA and AXB dose 
calculations agreed well with RPC lung phantom to 
TLD and film measurements for IMRT and VMAT 
plans. The cause for this small difference between 
AXB and AAA is attributed to the modeling of the 
heterogeneity of lung tissue in the AXB, compared 
to AAA, as reported by other studies [21]. Rob-
inson D [22] has demonstrated that AAA overes-
timates the doses to the heterogeneity interface. 
Supporting this finding, Liu et al. [23] have also 
reported lower conformity (–2.1%), compared to 
AAA.  Tajaldeen et al. [24] showed 2.3%, 1.3% and 
0.7% discrepancies between AAA, AXBw and AXBm 
algorithms and measured dose, respectively. Kumar 
et al. [25] found less than 1% discrepancy between 
AAA and AXB for mean PTV dose in deep-inspi-
ration breath-hold respiratory techniques used for 
the treatment of left breast cancer.
In 2002, Liu [8] asserted that the dose-to-medi-
um method allows a closer relationship between 
tissue response and dose, while Keall Paul argued 
against this statement and specified that all clinical 
knowledge and dosimetry protocols are based on 
the dose-to-water mode.
Eclipse AXB is based on the macroscopic cross 
sections of the media assigned from the CT scan 
for transport of photons and electrons. A biological 
material, such as the lung, adipose tissue, muscle, 
cartilage, or bone, can be assigned for voxels with 
a density < 3 g/cm3. The voxels are assigned a ma-
terial design corresponding to the weighted pro-
portion of the materials, when the density ranges 
overlap (e.g., adipose and muscle). AXBm used the 
energy deposition cross section or restricted elec-
tronic stopping power from the medium at that 
point. AXBm is then intrinsically computed so that 
the TPS reference dose should be specified in water, 
because the difference between water and tissue is 
inherently captured [26]. 
The results emphasize that several factors af-
fect plan evaluation when using the Octavius®‐4D 
phantom. They are especially improved if the more 
limiting local γ‐index computation approach is 
used. Indeed, the global γ‐index produces more 
homogeneous results with higher passing rates, be-
cause its tolerance level is computed with respect 
to the value of the maximum dose. The 2D ap-
proach considers each slice as independent of the 
surrounding volume, with the drawback that the 
table 4. an overview of literature comparisons to current study
Literature data Pathologies Treatment technique AAA vs. AXbm
Current study
AAA vs. AXbm AAA vs. AXbw
Fogliata a et al. 2012 lung VMat < 0.5% 2.6% 3.0%
Rana S et al. 2013 Prostate VMat 0.5% 0.67% -0.21%
Kan MW et al. 2013 head and neck VMat –2.0% 0.14% 1.01%
han t et al. 2013 lung phantom iMRt and VMat –2.2% 2.6% 3.0%
lui et al. 2014 lung SBRt –2.1% 2.6% 3.0%
hirata K et al. 2015 head and neck VMat 2.6% 0.14% 1.01%
Kumar l et al. 2020 Breast Breath hold 1.0% na na
Bassi S et al. 2020 Phantom study Static 1.8% na na
VMat — volumetric modulated arc therapy; iMRt — intensity modulated radiation therapy; SBRt — stereotactic body radiation therapy; na — not applicable
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results are strongly dependent on the chosen plane, 
without a certain significant correlation between 
the magnitude of errors of different plans [27]. The 
3D analysis allows a slice‐by‐slice evaluation, also 
considering the neighboring slices. Our results 
confirmed that the single slice evaluation (2D) al-
ways had an inferior agreement, compared to the 
3D analysis and volumetric γ‐index. Pulliam et al. 
[28] compared the two gamma results, using Monte 
Carlo computation as reference dose distribution, 
and quantified the increase of the passing pixels 
percent up to 3.2% in the 3D analysis, confirming 
our findings. Moreover, some problems that would 
be identified with 3D analysis might be missed in 
2D individual planes. The 3D analysis could also 
highlight local regions where problems exist. 
conclusion
In the present study, the results showed that doses 
calculated to medium by AXBm could be used clini-
cally for VMAT application. Moving from AAA to 
AXB does not require extra measurements because 
the dose difference between AAA and AXB were 
small in prostate and head and neck pathologies. 
However, the appropriateness of switching the dose 
calculation algorithm from AAA to AXB should 
be confirmed carefully from a clinical viewpoint 
in lung pathologies. AXBm results in advantage not 
only for prostate and head and neck but also for 
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